UmbREALung - A Retrospective and prospective, observational, real world multi-cohort study of patients with non-small cell lung cancer (NSCLC) initiating approved drugs developed by AZ or as part of an AZ alliance

Trial Identifier: D4191R00060
Sponsor: AstraZeneca
Start Date: December 2024
Primary Completion Date: June 2032
Study Completion Date: June 2032

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
France AIX EN PROVENCE, France
France ANGERS, France
France AURILLAC, France
France AUXERRE, France
France AVIGNON, France
France BLOIS, France
France BORDEAUX, France
France BOURG EN BRESSE, France
France CARCASSONNE, France
France Chalon sur Saone, France
France Chambery, France
France CHATEAUROUX, France
France CRETEIL, France
France DIEPPE, France
France DINAN, France
France DREUX, France
France Epagny Metz Tessy, France
France Le COUDRAY, France
France LIMOGES, France
France Lyon, France
France LYON, France
France MARSEILLE, France
France MEAUX, France
France METZ, France
France MULHOUSE, France
France NANCY, France
France NANTES, France
France NEUILLY SUR SEINE, France
France NICE, France
France Nîmes, France
France PERPIGNAN, France
France ST BRIEUC, France
France ST ETIENNE, France
France ST HERBLAIN, France
France SURESNES, France
France TOULOUSE, France
France TROYES, France
France VALENCIENNES, France
France VANNES, France
France VILLEFRANCHE SUR SAONE, France
France VILLEURBANNE, France